<DOC>
	<DOCNO>NCT01379508</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety follow Roadmap Concept strategy initial monotherapy use either telbivudine tenofovir HBeAg negative CHB patient . The data study allow validation Roadmap concept prospective manner , telbivudine tenofovir treat HBeAg negative CHB patient . As part post-approval commitment European Health Authorities , data also use provide optimized clinical treatment strategy well clinical use telbivudine European HBeAg negative patient . Furthermore , data study contribute good scientific understanding , disease management treatment HBeAg negative CHB patient .</brief_summary>
	<brief_title>Telbivudine Tenofovir Treatment HBeAg-negative Chronic Hepatitis B Patients Based Roadmap Concept</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Male female , least 18 year age Documented compensated HBeAg negative CHB define follow : Detectable serum HBsAg screen visit least 6 month prior ; HBeAg negative screen visit positive HBeAb ; Serum HBV DNA &gt; 2000 IU/mL Serum ALT level &gt; 1×ULN &lt; 10×ULN screen visit ; patient normal ALT ≤1xULN screen eligible , moderate liver inflammation fibrosis , complensated liver sirrhosis , ALT level &gt; 1xULN wtihin last 6 month Coinfected HCV , HDV HIV . Received treatment nucleoside nucleotide drug time Received IFN immunomodulatory treatment within six month Screening Pregnant nursing ( lactate ) woman Clinical signs/symptoms hepatic decompensation History myopathy , myositis persistent muscle weakness history clinical laboratory evidence chronic renal insufficency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>